Bain Capital To Acquire DSM Sinochem Pharmaceuticals
By

Bain Capital Private Equity, a private investment firm, has agreed to acquire DSM Sinochem Pharmaceuticals (DSP), a Singapore-headquartered producer of antibiotics, statins, and antifungals.

DSP is a 50/50 joint venture of Royal DSM, a life sciences and material sciences company, and Sinochem Group, a Fortune 500 enterprise.

DSP develops, produces, and sells intermediates, active pharmaceutical ingredients, and finished dosage form pharmaceuticals. In 2017, the company generated sales of approximately EUR 440 million ($516 million). It has manufacturing sites and sales offices in China, India, the Netherlands, Spain, the US, and Mexico, with approximately 2,000 employees.

The transaction is expected to be completed in the fourth quarter of 2018, subject to customary regulatory approvals and consultations.

Source: DSM Sinochem Pharmaceuticals

Leave a Reply

Your email address will not be published. Required fields are marked *